Valuation: Alkem Laboratories Limited

Market Cap 678B 7.08B 6.22B 5.81B 5.33B 9.98B 10.22B 68.86B 26.93B 336B 26.58B 26B 1,160B P/E 2026
27.5x
P/E 2027 * 29x
Enterprise Value 650B 6.79B 5.96B 5.57B 5.11B 9.56B 9.8B 66B 25.81B 322B 25.48B 24.93B 1,112B EV / Sales 2026
4.3x
EV / Sales 2027 * 3.97x
Free-Float
37.56%
Yield 2026
1%
Yield 2027 * 0.91%
1 day+2.41%
1 week+3.70%
Current month+4.29%
1 month+4.29%
3 months+7.57%
6 months+2.32%
Current year+5.49%
1 week 5,561.5
Extreme 5561.5
5,882.5
1 month 5,487
Extreme 5487
5,882.5
Current year 5,075
Extreme 5075
5,933.5
1 year 4,738.5
Extreme 4738.5
5,933.5
3 years 3,447
Extreme 3447
6,439.9
5 years 2,828
Extreme 2828
6,439.9
10 years 1,455
Extreme 1455
6,439.9
Manager TitleAgeSince
President - -
President - -
Director of Finance/CFO - 2024-01-31
Director TitleAgeSince
Director/Board Member 44 2013-08-08
Director/Board Member 63 2008-02-10
Director/Board Member 44 2019-11-10
Change 5-day change 1-year change 3-year change Capi.($)
+2.75%+3.70%+13.91%+46.00% 7.08B
-0.87%+4.04%+58.60%+163.92% 1,079B
-0.45%+3.87%+57.95%+52.18% 640B
+0.04%+3.95%+37.69%+74.54% 465B
-0.82%+8.81%+39.38%+34.26% 353B
-0.53%+3.51%+36.97%+43.76% 301B
-0.84%+3.40%+17.71%+18.77% 271B
-0.64%+5.81%-2.55%-36.02% 228B
-1.39%+5.90%+27.70%+64.00% 209B
-1.18%+1.83%+16.20%+72.69% 165B
Average -0.13%+4.51%+30.36%+53.41% 371.68B
Weighted average by Cap. -0.50%+4.86%+41.87%+78.77%

Financials

2026 2027 *
Net sales 146B 1.53B 1.34B 1.25B 1.15B 2.15B 2.2B 14.85B 5.81B 72.36B 5.73B 5.61B 250B 165B 1.73B 1.52B 1.42B 1.3B 2.43B 2.49B 16.79B 6.57B 81.83B 6.48B 6.34B 283B
Net income 25.13B 262M 231M 215M 197M 370M 379M 2.55B 998M 12.43B 985M 964M 42.98B 23.59B 246M 216M 202M 185M 347M 356M 2.4B 937M 11.67B 925M 905M 40.35B
Net Debt -28.13B -294M -258M -241M -221M -414M -424M -2.86B -1.12B -13.92B -1.1B -1.08B -48.13B -21.73B -227M -199M -186M -171M -320M -328M -2.21B -863M -10.75B -852M -833M -37.18B
Logo Alkem Laboratories Limited
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Employees
18,785
Date Price Change Volume
26-07-30 5,826.00 +2.71% 238,212
26-07-29 ₹5,672.50 +0.37% 57,547
26-07-28 ₹5,651.50 +0.69% 58,815
26-07-27 ₹5,613.00 -0.36% 112,113
26-07-24 ₹5,633.50 +0.56% 55,151
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
5,672.50INR
Average target price
5,964.80INR
Spread / Average Target
+5.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKEM Stock